Ontology highlight
ABSTRACT:
SUBMITTER: Tan L
PROVIDER: S-EPMC10902357 | biostudies-literature | 2024 Feb
REPOSITORIES: biostudies-literature
Tan Lavinia L Brown Chris C Mersiades Antony A Lee Chee Khoon CK John Thomas T Kao Steven S Newnham Genni G O'Byrne Kenneth K Parakh Sagun S Bray Victoria V Jasas Kevin K Yip Sonia S Wong Stephen Q SQ Ftouni Sarah S Guinto Jerick J Chandrashekar Sushma S Clarke Stephen S Pavlakis Nick N Stockler Martin R MR Dawson Sarah-Jane SJ Solomon Benjamin J BJ
Nature communications 20240228 1
In this phase II, single arm trial (ACTRN12617000720314), we investigate if alternating osimertinib and gefitinib would delay the development of resistance to osimertinib in advanced, non-small cell lung cancer (NSCLC) with the epidermal growth factor receptor (EGFR) T790M mutation (n = 47) by modulating selective pressure on resistant clones. The primary endpoint is progression free-survival (PFS) rate at 12 months, and secondary endpoints include: feasibility of alternating therapy, overall re ...[more]